---
title: "Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Guidelines questions"
description: "Guidelines questions on Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Does NCCN recommend KEYTRUDA for early-stage triple-negative breast cancer? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/guidelines"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Guidelines questions

Manufacturer: Merck Sharp & Dohme LLC  
Prescribing information: [Keytruda](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf)

## Guidelines

<a id="keytruda-nccn-recommendation"></a>

### Does NCCN recommend KEYTRUDA for early-stage triple-negative breast cancer?

> “NCCN CATEGORY 1 PREFERRED: Pembrolizumab (KEYTRUDA) as Part of a Treatment Option for Certain Patients With High-Risk Early-Stage (Stage II–III) TNBC for Neoadjuvant Followed by Adjuvant Therapy<sup>4</sup>
>
> Preoperative pembrolizumab (KEYTRUDA) in combination with carboplatin + paclitaxel, followed by preoperative pembrolizumab (KEYTRUDA) in combination with cyclophosphamide + doxorubicin or epirubicin, followed by adjuvant pembrolizumab (KEYTRUDA)<sup>4</sup>”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=NCCN%20CATEGORY%201%20PREFERRED%3A%20Pembrolizumab,epirubicin%2C%20followed%20by%20adjuvant%20pembrolizumab)

> “Category 1 = Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.<sup>4</sup>”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=Category%201%20%3D%20Based%20upon,Panel%29%20that%20the%20intervention%20is)

## Related pages
- [Medical information: Keytruda (pembrolizumab): High-risk early-stage triple-negative breast cancer](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/access-and-coverage)
